MedTrace Logo

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

NCT02572167 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2022-11-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)

Conditions

Interventions

DRUG

brentuximab vedotin

1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles

DRUG

nivolumab

3 mg/kg by intravenous (IV) infusion for up to 4 cycles

Sponsors & Collaborators

Principal Investigators

  • Faith Galderisi, DO · Seagen Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-03-01
Completion
2021-10-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02572167 on ClinicalTrials.gov